Categories
Featured Health Care Stocks Investing Stock Market Today

What Stocks To Buy Today? 4 Health Care Stocks To Know

Given the uncertainties in the stock market now, could health care stocks be back in focus?

Are These The Top Health Care Stocks To Buy Now?

Health care stocks may not be as hot as they were in the stock market back in 2020. However, there are always hidden gems waiting to be found in this sector. Amidst the global pandemic, could you imagine how severe the situation would be without proper access to health care services and heavy investments into the research of vaccination? Some may take health care for granted but the pandemic has reminded us of the importance of health care services. Fortunately, given the pace with which health care services and technology are advancing, many illnesses are no longer incurable.   

For instance, Atossa Therapeutics Inc (NASDAQ: ATOS) will be holding a webinar on June 9, 2021, to discuss its latest clinical development. It will be releasing and discussing the final data from its Phase 2 study of Endoxifen administered to breast cancer patients prior to surgery. Investors reacted positively to the news and ATOS stock soared by over 80% over the past week. This reinforces the notion that health care stocks could bring huge gains if one conducts proper research. If this form of investment gets you excited, here’s a list of top health care stocks in the stock market today.

Top Health Care Stocks To Buy [Or Sell] Today

Biogen Inc 

Biogen is making the headlines right now and with good reasons. The company is a biopharmaceutical company that specializes in serious neurological, rare, and autoimmune diseases. On Monday, BIIB stock soared by a staggering 38.34% to close at $395.85. This came as investors responded favorably to Biogen’s latest news regarding its Alzheimer’s drug, ADUHELM™ (aducanumab-avwa). 

On Monday, Biogen and Eisai, Co, Ltd (OTCMKTS: ESALY) announced that the FDA has granted accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment. The accelerated approval was granted based on data from clinical trials showing the effect of the drug on reducing amyloid-beta plaques, a biomarker that is likely to predict clinical benefit. In this case, a reduction in clinical decline. 

This is a historic moment as decades of groundbreaking research have been dedicated to the field of Alzheimer’s disease. With this, there will be hope for people living with Alzheimer’s disease and hopefully spark continuous innovations in the years to come. Hence, would you consider BIIB stock a top health care stock to buy now? 

Source: TD Ameritrade TOS

[Read More] C3.ai (AI) Vs Palantir Technologies (PLTR): Which Artificial Intelligence Stock Is The Better Buy?

Novo Nordisk A/S 

Another trending health care company would be Novo. The company is a global health care company that engages in diabetes care. It also engages in the discovery, development, manufacturing, and marketing of pharmaceutical products. Essentially, it operates two segments, diabetes, and obesity care. NVO stock has risen over 25% over the past year. 

Last week, the company finally gained the FDA approval for a once-weekly Wegovy (semaglutide) 2.4 mg injection, for chronic weight management. Wegovy is the first weight management drug approved for chronic obesity and overweight adults since 2014. Based on its phase 3 data, this drug will be used in conjunction with diet and exercise. The data shows that the drug helped one-third of patients lose more than 20% of their body weight over the 68-week trial period. 

The drug would likely be a big hit once it hits the market as nearly 70% of American adults are affected by obesity. The drugmaker said it is expecting the launch in late June 2021. This is a big win for Novo which has seen its core insulin business face steep competition, prompting it to turn to newer diabetes and obesity drugs. With that in mind, would you consider buying NVO stock? 

Source: TD Ameritrade TOS

Read More

Eli Lilly And Co

Eli Lilly and Company is a drug manufacturing company. Essentially, it discovers, develops, manufactures, and markets products in a human pharmaceutical product segment. It appears that LLY stock has benefitted from the groundbreaking news of Biogen’s FDA approval for the Alzheimer’s disease drug. The stock soared by 10.15% and went as high as $233.33 on Monday’s trading session. 

So why would Biogen’s drug act as a catalyst to boost Lilly? This is because the company also has a drug candidate for treating Alzheimer’s disease which showed promising results from its phase 2 study. The drug known as Donanemab showed significant slowing of cognitive decline in patients with early Alzheimer’s compared to placebo. Thus, it is possible that investors are optimistic and hope that Lilly will also gain its approval for its drug candidate soon.  

On top of that, the company and Incyte (NASDAQ: INCY) also suggested that OLUMIANT® (baricitinib) 4 mg tablet could reduce pain and duration of morning joint stiffness, and improve overall physical function at 12 weeks. In the test compared with HUMIRA® (adalimumab) and placebo, the tested patients are those with moderate to severe rheumatoid arthritis. This is significant because, despite available treatment options, patients still live with symptoms that may limit their day-to-day activities. All things considered, would you bet on LLY stock’s future?

Source: TD Ameritrade TOS

[Read More] 4 Artificial Intelligence Stocks To Watch Right Now

Medtronic PLC

Last on the list, we have the medical technology and services company, Medtronic. It develops, manufactures, and markets its medical devices to approximately 160 countries. If you are a fan of a stock that climbs slowly but consistently, then MDT stock may be the one for you. The stock has climbed by over 20% over the past year.  

On Tuesday, Medtronic announced the clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal LINQ™ Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats. The company compares it to the standard of care in both large and small vessel stroke patients. It is a known fact that Atrial Fibrillation (AF) is a major risk factor for ischemic stroke. In fact, the risk increases by five-fold in AF patients. So, higher rates of detection of AF are of high importance. 

Furthermore, the company has also gained FDA approval for the first U.S. implants of the SenSight™ Directional Lead System used for Deep Brain Stimulation (DBS) therapy. This would allow physicians to deliver precise, patient-specific DBS therapy for the treatment of certain symptoms associated with movement disorders. Given all the recent developments of the company, would now be the best time to invest in MDT stock?

By Amos C

Amos is the global markets correspondent for StockMarket.com. His boots on the ground insight into emerging markets has given him the unique ability to stay ahead of new market trends and deliver timely data when it matters most. Based in Asia, Amos has made a point to monitor the foreign markets closely, dissect stock market trends and then apply them to the North American markets; in addition to global markets.

Amos has a deep-rooted background in foreign exchange and commodities. His previous experience working within the cryptocurrency arena has given him the advantage to identify the fast-moving stock market and financial trends. Amos calls Hong Kong home and has been a financial content writer for the last 3 years.

He has managed teams of international media strategists and financial writers to cover all top stories in the stock market each day. His skills include his tireless drive to find the most valid information and actionable details that investors can use to formulate valid decisions on stocks to buy or stocks to avoid. Furthermore, Amos’ ability to cover trending stories across the globe brings StockMarket.com a fresh perspective on key data and how it not only affects the North American markets but also how it could translate to the world markets alike.

Most of the time you can find him diving into corporate filings, focusing on fundamentals that could influence major market moves. One of his passions is researching technology and biotechnology stocks. Some of the most cutting-edge innovations have stemmed from these industries. While many don’t become industry blockbusters, the processes and applications of these innovations has led to some of the biggest developments known to man in the modern age. As a global correspondent, Amos has been able to see both sides of the story as it relates to world news and offers a true, personal approach, cutting through the noise of the mass media. He was integral in reporting on the Hong Kong uprising and doing first-hand research on international sentiment from the novel coronavirus.

In his free time, Amos is an avid fan of music and art and enjoys attending concerts.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments